[ad_1]
Brady Granier, CEO of BioCorRx Inc. (OTCQB: BICX), told Proactive Investors that the California-based substance use disorder treatment developer had received a $ 5.7 million grant from National Institutes of Health for the development of BICX102 naltrexone implant for the treatment of opioid dependence and alcoholism.
Mr Granier said that once the implant was approved, he envisioned that the company would combine its Cognitive Behavioral Therapy and Peer Support Program to provide more tools to patients. doctors who prescribe the product.
Source link
